Deficiency of those pro-inflammatory cytokines results in reduced colitis and anti-cytokine therapies involving TNF-specific agents composes an important part of clinical therapy in IBD treatment [53,54,55,56]. The gene discussed is TNF; the disease is inflammatory bowel disease.